Neuronetics, Inc. (STIM) News

Neuronetics, Inc. (STIM): $2.57

-0.14 (-5.17%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add STIM to Watchlist
Sign Up

Filter STIM News Items

STIM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

STIM News Highlights

  • For STIM, its 30 day story count is now at 21.
  • Over the past 25 days, the trend for STIM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • AMP, DRUG and ICD are the most mentioned tickers in articles about STIM.

Latest STIM News From Around the Web

Below are the latest news stories about NEURONETICS INC that investors may wish to consider to help them evaluate STIM as an investment opportunity.

Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes

Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.

Yahoo | June 2, 2023

Neogen (NEOG) Introduces 2 Assays for Histamine Detection

Neogen (NEOG) launches Reveal for Histamine and Reveal Q+ for Histamine assays for the detection of Histamine.

Yahoo | June 2, 2023

LabCorp (LH) Expands Precision Oncology With Biopsy Test

The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.

Yahoo | June 1, 2023

Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23

At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.

Yahoo | May 31, 2023

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Yahoo | May 29, 2023

Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan

Lower Medication Requirement Helps Depression Patients Obtain Treatment SoonerMALVERN, Pa., May 26, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced a healthcare policy update from BlueCross BlueShield (BCBS) of Michigan that expands eligibility for depression patients to receive transcranial magnetic

Yahoo | May 26, 2023

Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio

Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.

Yahoo | May 25, 2023

Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference

MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or “Neuronetics”), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023. The Company is scheduled to present at 1:00 pm Eastern Tim

Yahoo | May 24, 2023

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Yahoo | May 24, 2023

Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

Yahoo | May 23, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8803 seconds.